1981
High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.
Jones R, Collins J, Myers C, Brooks A, Hubbard S, Balow J, Brennan M, Dedrick R, DeVita V. High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Research 1981, 41: 55-9. PMID: 7448776.Peer-Reviewed Original ResearchConceptsEpisodes of bacterial peritonitisNovel treatment modalitiesTotal body clearanceIntraperitoneal chemotherapyPeritoneal irritationChemotherapeutic regimensMethotrexate clearanceBacterial peritonitisOvarian cancerMalignant melanomaTreatment modalitiesLocal toxicitySystemic toxicityPlasma levelsPeritoneal cavitySystemic circulationTreatment cyclesPlasma concentrationsMethotrexate concentrationsTherapeutic benefitBody clearancePatientsMethotrexateChemotherapyPeritonitis
1980
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.
Speyer J, Collins J, Dedrick R, Brennan M, Buckpitt A, Londer H, DeVita V, Myers C. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Research 1980, 40: 567-72. PMID: 7471076.Peer-Reviewed Original ResearchConceptsPeritoneal fluid concentrationsPlasma levelsGram-negative bacterial peritonitisTenckhoff peritoneal dialysis catheterCentral nervous system toxicityStudy of 5-fluorouracilDose-limiting toxicityPeritoneal fluid levelsSimultaneously measured plasma levelsPhase I studyPeritoneal dialysis catheterNervous system toxicityMild abdominal discomfortRoute of administrationTotal body clearanceFluid concentrationsPattern of toxicityBacterial peritonitisDialysis catheterAbdominal discomfortSystemic toxicityPharmacological advantagesDialysate concentrationsBody clearanceFluid levels